ITEM 8.01.
Other Events.
On July 2, 2019, further to the previously announced recommended cash offer (the “
Acquisition
”), to acquire the entire issued and to be issued ordinary share capital of BTG plc (“
BTG
”)
by Bravo Bidco Limited, an indirect wholly-owned subsidiary of Boston Scientific Corporation (“
Boston Scientific
”), BTG and Boston Scientific issued an
announcement on the London-based Regulatory News Service (“
RNS
”), disclosing that Boston Scientific signed an agreement for the sale of its existing
drug-eluting and bland embolic microsphere business (including ONCOZENE
TM
, EMBOZENE
TM
and EMBOZONE TANDEM
TM
) to Varian Medical Systems, Inc.
The sale is subject to the
satisfaction or waiver of customary closing conditions, including consummation of the Acquisition, and is expected to close immediately after completion of the Acquisition.
A copy of the aforementioned RNS announcement is attached as Exhibit 99.1 and is incorporated herein by reference;
provided, however, that information on or connected to our website or the website of any third-party hyperlinked from or referenced in the RNS announcement included as Exhibit 99.1 to this Current Report on Form 8-K is expressly not incorporated by
reference into or intended to be filed as a part of this Current Report on Form 8-K.
